// App-Quantinova.ai

353.0 : Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.

Researchers

Presenter

  • Sharlene Gill

Principal Investigators

  • Dena H Jaffe

  • Marc DeCongelio

  • Arnold N. DuBell

  • Jing Shi

  • Tami Wisniewski

  • Gwilym Thompson

Medical Centers

  • BC Cancer Agency, Vancouver, BC, Canada

  • Kantar Health, Tel Aviv, Israel

  • Kantar Health, Horsham, PA

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bristol-Myers Squibb, Uxbridge, United Kingdom

Locations

  • Canada

  • Israel

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Sorafenib

Outcome

  • N/A

Study Design

  • Non Interventional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved